Skip to main content

Table 1 Summary of HCV vaccine candidates based on E1/E2 glycoproteins in preclinical or clinical trials

From: Hepatitis C virus vaccine design: focus on the humoral immune response

Vaccine / HCV genotype

Target

Cross-genotype neutralization activity using HCVpp and/or HCVcc

Immunized species

Refs

rE2(Δ123) and rE2(Δ123A7) / HCV 1a (H77c)

E2

1a (H77), 2a (J6), 3a (S52), 5a (SA13)

Guinea pigs

[31]

rHCV E1/E2 with admixed sulfated S-lactosylarchaeol (SLA) archaeosome formulation as adjuvant / HCV 1a (H77)

E1E2

N/A

C57BL/6 x BALB/c F1 mice

[32]

HCVp6-MAP. Six peptides (p6) in a multiple antigenic peptide (MAP) derived from conserved epitopes in E1 (1), E2 (2), NS4B (1), NS5A (1) and NS5B (1) / HCV 4a (ED43)

E1, E2, NS4b, NS5a, NS5b

2a (JFH1) and a chimeric 2a/4a (ED43/JFH1)

BALB/c mice

[33]

DNA vaccine encoding sE1E2 into IMX313P (oligomers by fusion with the oligomerization domain of the C4b-binding protein) or sE1 and sE2 as separate immunogens / HCV 1b (HCV-N)

E1, E2, E1E2

1a (H77.20, UKN1A20.8), 1b (ukn1b5.23), 2a (ukn2a1.2, a2.4), 2b (UKN2B1.1, B2.8), 3a (UKN3A1.28, A1.9, A13.6), 4a (UKN4.11.1, 4.21.16), 5 (UKN5.14.4), 6 (UKN6.5.8, 6.5.340)

BALB/c mice

[34]

HCV-like particles bearing core, E1 and E2 from four genotypes / 1a (H77), 1b (BK), 2a (JFH1), and 3a

E1, E2, core

1a (H77), 1b (BK), 2a (JFH1/J6, JFH1), 3a (HIC-109)

BALB/c mice

White Landrace pigs

[35, 36]

Chimeric HBV/HCV virus‐like particles bearing three conservative linear epitopes from E1 and E2 and HVR1 mimotope / N/D

E1, E2

1a (JFH1/H77, H77C/JFH1), 1b (Hebei, J4/JFH1), 2a (JFH1/J6, JFH1)

BALB/c mice

[37]

rE2(Δ123) / HCV 1a (H77c)

E2

1a (H77c), 2a (J6), 3a (S52), 4a (ED43), 5a (SA13), 6a (EUHK2), 7a (QC69)

Albino Dunkin Hartley guinea pigs

[38]

rHCV E1/E2 with MF59C.1 as an adjuvant / HCV 1a

E1E2

Genotype 1a/1b patients

Humans (Phase Ib)

[39]

Chimeric HBV/HCV virus‐like particles bearing E1 or E2 /

HCV 1a (JFH1/H77)

E1, E2

1a (JFH1/H77; 7a), 1b (JFH1/J4; UKN5.23), 2a (JFH1 WT; UKN 2a1.2), 3 (JFH1/S52; UKN3A.1.28)

New Zealand rabbits

[40]

rHCV E1E2 / HCV 1a (HCV-1)

E1E2

1a (H77), 2a (J6), 3a (S52), 4a (ED43), 5a (SA13), 6a (HK6a)

Chimpanzees

[41]

HCV virus-like particles bearing E1E2 or E1 / HCV 1a (H77)

E1, E1E2

1a (H77), 1b (CG1b, CON1), 2a (JFH-1), 2b (UKN2B), 4c (UKN4)

Macaques (Macaca fascicularis)

Human CD46 ± IFNαβR-/- mice

[42]

rHCV E1/E2 with MF59C.1 as an adjuvant (oil-in water emulsion) / HCV 1a

E1E2

1a (HCV-1, H77), 1b (UKN1B 12.6), 2a (J6), 3a (S52), 4a (UKN4.11.1), 5a (SA13)

C57BL/6J mice, macaques (Macaca mulatta), humans (Phase I, NCT00500747)

[43,44,45,46]

DNA vaccine expressing HCV Core, E1 and E2 / HCV 1b (CIGB-230)

E1, E2, core

N/A

Humans (Phase I)

[47,48,49]

HCV virus‐like particles bearing core, E1, and E2 with AS01B as an adjuvant (a combination of monophosphoryl lipid A and QS21 saponin) / HCV 1b (CG1b)

E1, E2, core

N/A

Chimpanzees (Pan Troglodytes)

[50]

rHCV E1 with aluminum hydroxide as an adjuvant / HCV 1b

E1

N/A

Humans (Phase I)

[51]

DNA vaccine expressing HCV E2 / HCV 1a

E2

N/A

Chimpanzees (Pan Troglodytes)

[52]

  1. Δ123: E2‐receptor‐binding domain lacking hypervariable region (HVR) 1 and 2, and the intergenotypic variable region (igVR) (384-408) or replaced with glutathione disulfide linkers (461-485 and570-580); Δ123A7: a disulfide-minimized version that contains seven cysteine to alanine mutations (A7: C452A, C486A, C569A, C581A, C585A, C597A, C652A); HCVcc: cell-cultured viruses; HCVpp: HCV pseudoparticles; N/A: Cross-reactive neutralizing antibodies not evaluated; N/D: Origin not indicated